Sessa Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Sessa Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-249,000	Closed	-$3.51M	–	32
2022 Q2	$3.51M	Hold	249,000	–	–	0.19%	29
2022 Q1	$6.03M	Buy	+249,000	New	+$6.03M	0.29%	33

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sessa Capital's ACAD Position: Q3 2022 in Review

Sessa Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 249,000 shares — an estimated $3.51M sold.

Sessa Capital first reported a position in ACAD in Q1 2022 and held it in 2 quarters. The position peaked at $6.03M in Q1 2022. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

Sessa Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Sessa Capital sold 249,000 Acadia Pharmaceuticals shares in Q3 2022, an estimated $3.51M.
Sessa Capital first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 2 quarters.
Sessa Capital's Acadia Pharmaceuticals position peaked at $6.03M in Q1 2022.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Sessa Capital's 13F filing for Q3 2022, filed 14 Nov 2022.